The global medical tourism market is projected to grow at roughly 21% per year through 2030, according to newly compiled industry data — and China is emerging as one of the fastest-growing destinations for complex care.
Three forces are driving the surge. First, advanced therapies such as CAR-T immunotherapy, proton-beam radiotherapy and robotic surgery are now routinely available in Asia at a fraction of Western prices. Second, waiting lists in many public healthcare systems continue to lengthen, pushing patients to seek timely alternatives abroad. Third, transparent pricing and English-language coordination services — like those MyMedTour provides — have removed much of the uncertainty that once deterred international patients.
For patients considering treatment in Tianjin, the practical takeaway is simple: world-class tertiary hospitals now routinely accept international cases with all-inclusive quotations issued within 48 hours. From initial medical-record review to post-operative follow-up, a structured pathway exists for nearly every major specialty — cardiology, oncology, orthopedics, organ transplantation and preventive checkups among them.
Industry analysts expect the strongest growth in preventive and longevity-focused travel: comprehensive health checkups and early-detection imaging programs that combine a hospital-grade screening with a comfortable city stay.